Rigel Pharmaceuticals (RIGL)

Rigel’s marketed portfolio includes TAVALISSE, the brand name for fostamatinib, an oral spleen tyrosine kinase inhibitor used in adult patients with chronic immune thrombocytopenia who have had an insufficient response to previous treatment. The company also markets REZLIDHIA, an IDH1 inhibitor for certain patients with relapsed or refractory acute myeloid leukemia, and has rights to GAVRETO, a RET inhibitor used in selected oncology indications. These products give Rigel exposure to both hematology and targeted cancer treatment markets.

The company’s strategy combines internal research, clinical development, licensing, and commercial execution. Earlier in its history, Rigel partnered with larger pharmaceutical companies on drug candidates, including a rheumatoid arthritis programme licensed to AstraZeneca, under which Rigel’s economics were tied to milestone and royalty arrangements. Its pipeline continues to include investigational assets such as R289 and ocadusertib, reflecting an effort to expand beyond its existing revenue base.

For investors, Rigel is a specialist biopharmaceutical stock whose prospects depend on product adoption, clinical trial outcomes, regulatory decisions, reimbursement conditions, and its ability to manage the high costs and risks of drug development.